Regulatory Insights

  1. Why ddPCR Is Becoming The Standard For Gene Therapy Biodistribution 3/9/2026

    ddPCR is becoming essential for biodistribution because it delivers precise, low‑copy quantification qPCR can’t reliably match. Sponsors need partners with true ddPCR depth to ensure consistent, defensible data across tissues and studies.

  2. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  3. Why CGT Programs Need A Different CRO Mindset 3/9/2026

    Advanced therapies need bioanalysis partners built for complexity, not scale. CGT expertise, specialized platforms, and flexible timelines ensure dosing and safety data traditional CROs can’t support.

  4. The Bioanalysis Report You Actually Get Back Fast 3/9/2026

    Manual bioanalysis variability creates data noise. Automation replaces inconsistencies with repeatable processes that boost precision, support compliance, and deliver more reliable results.

  5. ICH E6(R3) Is Here: What Your Centralized Monitoring Strategy Needs 3/9/2026

    ICH E6(R3) turns best practices into regulatory mandates. Learn how to maintain sponsor accountability and implement proportionate centralized monitoring through a unified, auditable data layer.

  6. Paper COAs in 2026: It's Not Cheaper, It's Riskier 3/9/2026

    Learn why sticking with paper records is a faulty strategy and discover how hidden costs, transcription errors, and regulatory red flags make digital COAs the only safe choice for modern trials.

  7. Clinical Research Update: The New FDA Form 1572 is Available 3/5/2026

    Stay current with the latest FDA investigator filing updates. Learn when to transition to the new version and how to maintain compliance without unnecessary administrative re-work.

  8. FDA Updates Guidance For Written IRB Policies 3/5/2026

    Explore how updated FDA and HHS guidance harmonizes regulations, streamlines IRB operations, and strengthens oversight for complex clinical trials.

  9. Tailored Approach Supports Bladder Cancer Breakthrough 3/5/2026

    Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.

  10. Policy To Practice: PBM Reform, TrumpRx, And Global Drug Development 3/4/2026

    Policy shifts are reshaping PBM oversight, driving transparent drug‑pricing tools, and influencing global responses that affect affordability, access, and future pharma development.